Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey.

Period	Debt/Equity
2015-12-31	0.16
2016-12-31	0.44
2017-12-31	0.34
2018-12-31	0.26
2019-12-31	0.31
2020-12-31	0.13
2021-12-31	0.06
2022-12-31	0.08
2023-12-31	0.08
2024-12-31	0.06

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CLDX	$33.62	+3.73%	0.82M
3
4
5

Celldex Therapeutics Inc. (CLDX) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Celldex Therapeutics Inc. Data in Excel

More CLDX Financial Data